Professional US stock economic sensitivity analysis and beta calculations to understand market correlation and portfolio risk exposure to market movements. We help you position your portfolio appropriately based on your risk tolerance and overall market outlook and expectations. We provide beta analysis, sensitivity testing, and correlation to market factors for comprehensive risk assessment. Understand risk exposure with our comprehensive sensitivity analysis and beta calculations for better portfolio construction.
Climb Bio Inc. (CLYM) is a small-cap biotech stock trading at $6.8 per share as of 2026-04-06, registering a 3.66% gain in the most recent trading session. This analysis covers key technical levels to monitor for CLYM, recent trading context for both the stock and its broader sector, and potential near-term price scenarios based on current market data. No recent earnings data is available for Climb Bio Inc. as of this writing, so recent price action is largely driven by technical positioning and
Is Climb Bio (CLYM) Stock Consolidating | Price at $6.80, Up 3.66% - Long Term
CLYM - Stock Analysis
4750 Comments
1843 Likes
1
Toniya
Insight Reader
2 hours ago
If only I had read this earlier. 😔
👍 106
Reply
2
Jazmyn
Power User
5 hours ago
Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
👍 13
Reply
3
Anush
Loyal User
1 day ago
That’s some next-level stuff right there. 🎮
👍 200
Reply
4
Terion
Insight Reader
1 day ago
I read this and now I feel different.
👍 132
Reply
5
Yasmim
Legendary User
2 days ago
Great way to get a quick grasp on current trends.
👍 63
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.